Exhibit 99.3
2007 Consolidated Financial Guidance Summary
(in millions, except per share data)
(in millions, except per share data)
| Year Ended | Quarterly Revenue Range | |||||||||||||||||||||||
| December 31, 2007 | Q1 | Q2 | Q3 | Q4 | ||||||||||||||||||||
| Range | Range | Range | Range | Range | ||||||||||||||||||||
| WebMD | $ | 336.0 | $ | 352.0 | ||||||||||||||||||||
| ViPS | 105.5 | 109.0 | ||||||||||||||||||||||
| Porex | 89.5 | 93.0 | ||||||||||||||||||||||
| Total revenue | $ | 531.0 | $ | 554.0 | $ | 116.0 $120.0 | $ | 126.0 $130.0 | $ | 138.0 $145.0 | $ | 151.0 $159.0 | ||||||||||||
| Earnings before interest, taxes, non-cash and other items (“Adjusted EBITDA”)(a) | $ | 97.0 | $ | 108.0 | ||||||||||||||||||||
| Quarterly Mix | ||||||||||||||||||||||||
| Q1 | Q2 | Q3 | Q4 | |||||||||||||||||||||
| Reconciliation of Adjusted EBITDA to income from continuing operations: | ||||||||||||||||||||||||
| Interest income, net | 17.5 | 18.5 | 29% | 19% | 23% | 29% | ||||||||||||||||||
| Depreciation and amortization | (51.5 | ) | (50.5 | ) | 23% | 22% | 25% | 30% | ||||||||||||||||
| Non-cash advertising | (5.5 | ) | (5.0 | ) | 41% | 0% | 0% | 59% | ||||||||||||||||
| Non-cash stock-based compensation | (41.0 | ) | (40.0 | ) | 26% | 25% | 27% | 22% | ||||||||||||||||
| Income tax provision | (10.5 | ) | (12.5 | ) | 3% | 18% | 30% | 49% | ||||||||||||||||
| Equity in earnings of EBS Master LLC | 29.5 | 32.0 | 17% | 25% | 27% | 31% | ||||||||||||||||||
| Minority interest in WebMD Health Corp. | (3.0 | ) | (4.0 | ) | -12% | 13% | 34% | 65% | ||||||||||||||||
| Income from continuing operations | $ | 32.5 | $ | 46.5 | ||||||||||||||||||||
| Adjusted EBITDA per share | $ | 0.51 | $ | 0.57 | ||||||||||||||||||||
| Net income per share | $ | 0.17 | $ | 0.24 | ||||||||||||||||||||
| Weighted average shares — Diluted | 190.0 | 190.0 | ||||||||||||||||||||||
| (a) | See Annex A — Explanation of Non-GAAP Financial Measures |
Operating Segments
| Revenue | ||||
| * | WebMD — Refer to WebMD Health Corp. Financial Guidance Summary included in its February 21, 2007 press release. | |||
| * | ViPS — Approximately 24% of segment revenue in Q1 increasing to 26% in Q4. | |||
| * | Porex — Approximately 25% of segment revenue in Q1, 26% in Q2, 25% in Q3, and 24% in Q4. | |||
| Adjusted EBITDA | ||||
| * | WebMD — Refer to WebMD Health Corp. Financial Guidance Summary included in its February 21, 2007 press release. | |||
| * | ViPS — Approximately 19% of segment revenue in Q1 increasing to 21% thereafter. | |||
| * | Porex — Approximately 27% of segment revenue in Q1, 31% in Q2, 30% in Q3 and 29% in Q4. | |||
| * | Corporate — Approximately 6.2% of consolidated revenue in Q1 decreasing to 4.1% in Q4. | |||
| Other Assumptions | ||||
| * | The 2007 Guidance does not reflect any projected expenses related to the on-going Department of Justice investigation. | |||
| * | Additional details on WebMD’s guidance can be found in the press release issued by WebMD Health Corp. on February 21, 2007. | |||